Aspira Women’s Health Announces Appointment of Two New Board Members
June 23 2022 - 4:05PM
Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based
women’s health company focused on gynecologic disease, today
announced the appointments of two seasoned Board members: Dr.
Robert Auerbach and Ms. Ruby Sharma.
Dr. Auerbach retired President of CooperSurgical Inc., brings
extensive experience in the medical industry, including experience
as a director and as an executive officer. Ms. Sharma, Managing
Partner at RNB Strategic Advisors, brings decades of senior
leadership, accounting, and audit committee experience.
“We warmly welcome both Bob and Ruby to our Board. Each brings
different - but equally critical - skills and expertise to the
board. Bob’s medical background and track record of success as an
executive in the women’s health sector along with Ruby’s strategic
mindset and extensive financial, business and governance acumen
will be highly valuable to Aspira as we accelerate our strategic
execution in today’s challenging environment,” said Nicole
Sandford, CEO of Aspira Women’s Health.
Dr. Robert Auerbach, retired in 2020 as President of
CooperSurgical Inc., a wholly-owned subsidiary of CooperCompanies.
Having joined CooperSurgical in 2005, Dr. Auerbach previously held
Executive Vice President positions, including Chief Medical Officer
and Chief Strategy Officer. Dr. Auerbach continues to serve as an
adjunct faculty member and as an Executive Board Member of the
Center for Biomedical Innovation and Technology (CBIT) at Yale
University and has also been a member of the Yale School of
Medicine clinical faculty. He currently serves on the Board of
Directors of OCON Healthcare, Escala Medical, Empress Medical,
AblaCare, as well as an advisor to CooperSurgical and GestVision.
He is a graduate of the Lehigh-Hahnemann 6-year BA-MD program and
completed his OB/GYN residency at Yale.
Ms. Ruby Sharma, a seasoned professional and qualified audit
committee financial expert, is a Managing Partner at RNB Strategic
Advisors. Ruby serves as a member of the board of directors of
Nautilus, Inc. (NYSE: NLS) and ShotSpotter, Inc. (NASDAQ: SSTI) and
previously served as a Trustee and chair of the audit committee at
Penn Medicine Princeton Health. Ruby retired in 2017 as Senior
Partner from Ernst & Young LLP and has also held senior
management positions with Arthur Andersen, LLP and Grant Thornton
GmbH. Ms. Sharma is a Fellow Chartered Accountant and holds a B. A.
in Economics from Delhi University, India. Ms. Sharma has also
attended Executive Education program for EY Partners at
Northwestern University, Kellogg School of Management.
About Aspira Women’s Health Inc.Aspira Women’s
Health Inc. is transforming women’s health with the discovery,
development, and commercialization of innovative testing options
and bio-analytical solutions that help physicians assess risk,
optimize patient management, and improve gynecologic health
outcomes for women. Aspira Women’s Health is particularly focused
on closing the ethnic disparity gap in ovarian cancer risk
assessment and developing solutions for pelvic diseases such as
pelvic mass risk assessment and endometriosis.
OVA1plus™ combines our FDA-cleared products, OVA1® and
OVERA®, to detect risk of ovarian malignancy in women with adnexal
masses. Aspira GenetiX™ testing offers both targeted and
comprehensive genetic testing options with a gynecologic focus.
With over 10 years of expertise in ovarian cancer risk assessment,
Aspira Women’s Health is working to deliver a portfolio of pelvic
mass products over a patient’s lifetime with our cutting-edge
research. The next generation of products in development include
OVAWatch™ and EndoCheck™. To improve patient accessibility,
Aspira Women’s Health has recently launched our Aspira
Synergy™ technology transfer platform to empower health
systems, academics, regional labs, and physician group labs to
conduct genetic and specialty tests in-house. Visit our website for
more information at www.aspirawh.com.
Forward-Looking StatementsThis
press release contains forward-looking statements, as defined in
the Private Securities Litigation Reform Act of 1995, including
statements regarding, without limitation, the Company’s plans,
forecasts, projections, potential expansion and focus, current and
future test offerings. These statements involve a number of risks
and uncertainties. All statements other than statements of
historical facts contained in this press release are
forward-looking statements. Words such as “may,” “expects,”
“intends,” “anticipates,” “believes,” “estimates,” “plans,”
“seeks,” “could,” “should,” “continue,” “will,” “potential,”
“projects” and similar expressions are intended to identify
forward-looking statements. These forward-looking statements speak
only as of the date of this press release and are subject to a
number of risks, uncertainties, and assumptions, including the
risks and uncertainties described in the section entitled “Risk
Factors” in Aspira Women’s Health’s Annual Report on Form 10Q,
dated May 11, 2022. The events and circumstances reflected in
Aspira Women’s Health’s forward-looking statements may not be
achieved or occur and actual results could differ materially from
those projected in the forward-looking statements. Aspira Women’s
Health expressly disclaims any obligation to update, amend or
clarify any forward-looking statements to reflect events, new
information or circumstances occurring after the date of this press
release, except as required by law.
Investor Relations
Contact:Ashley R. RobinsonLifeSci Advisors, LLCTel
617-430-7577
Nautilus (NYSE:NLS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nautilus (NYSE:NLS)
Historical Stock Chart
From Jul 2023 to Jul 2024